Ophthalmology executives share challenging situations they encountered, as well as the steps needed to overcome the challenge.

Learn more about your ad choices. Visit megaphone.fm/adchoices

B+L launches a new scleral lenses technology in the US; New World Medical introduces a transparent tip on its Streamline Surgical System, and an OCT platform is cleared in Europe.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Bausch + Lomb receives CE Mark for a new full range of vision IOL; Aldeyra plans to once again resubmit a new drug application to the FDA for dry eye drug candidate reproxalap; and Topcon makes several deals to advance its AI and digital health solutions

Learn more about your ad choices. Visit megaphone.fm/adchoices

Commercial stakeholders discuss the challenges and opportunities in ophthalmology in this special edition of Eyewire News: The Podcast.

Learn more about your ad choices. Visit megaphone.fm/adchoices

EyewireTV reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery (ASCRS) meeting in Los Angeles.

Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA responds to Regeneron’s request to extend dosing intervals for Eylea HD; Regeneron applies for a new indication for Eylea HD; and several recent executive appointments are announced in the ophthalmology industry.

Learn more about your ad choices. Visit megaphone.fm/adchoices

A presbyopia drop is officially launched in the US; Nordic Pharma receives European approval for its novel dry eye therapy; and Tenpoint submits an NDA for a presbyopia eye drop candidate.

Learn more about your ad choices. Visit megaphone.fm/adchoices

EyewireTV speaks with the leaders of Digital Diagnostics and AEYE Health about their diabetic screening technology, racial and socioeconomic disparities in eye care, and their mission to improve health equity by expanding their technology into underserved populations.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Alcon introduces its next-generation trifocal IOL; Alcon announces a deal to advance its clinical-stage allogeneic cell therapy; and Bausch + Lomb announces a voluntary recall of IOLs on its enVista platform.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Alcon makes a major acquisition to bolster its cataract surgery portfolio; Opthea releases phase results for its combination wet AMD candidate; and Bausch + Lomb announces results from a phase 4 extension study of dry eye disease drug Miebo.

Learn more about your ad choices. Visit megaphone.fm/adchoices